Genes, access, and GLP‑1s

Glucagon-like peptide-1 drugs copy a gut hormone that helps control blood sugar and appetite, but new research suggests about 1 in 10 people carry gene variants that can blunt that effect. (med.stanford.edu) Stanford Medicine researchers said on April 10 that those variants appear to create “GLP-1 resistance,” a pattern in which the body has higher GLP-1 levels but gets less biological benefit from them. Their study, published in *Genome Medicine*, focused on blood-sugar control, not weight loss. (med.stanford.edu) A separate *Nature* paper published on April 8 looked at 27,885 people using glucagon-like peptide-1 medicines and found genetic differences tied to both weight-loss response and side effects such as nausea or vomiting. One variant in the GLP1R gene was linked to an extra 0.76 kilograms of weight loss per copy of the effect allele. (nature.com) That helps explain why patients on the same drug can have very different results. Stanford’s team said some people with the newly identified variants were less able to lower blood glucose after six months of treatment, which is often when doctors switch therapies. (med.stanford.edu) The access story is shifting at the same time. Eli Lilly said on April 1 that the United States Food and Drug Administration approved Foundayo, the brand name for orforglipron, as a once-daily pill for adults with obesity or overweight plus weight-related medical problems. (investor.lilly.com) Lilly said adults on the highest dose in the ATTAIN-1 trial lost an average of 27.3 pounds, or 12.4% of body weight, if they stayed on treatment. The company also said it has submitted orforglipron for obesity or type 2 diabetes in more than 40 countries and plans launches shortly after local approvals. (investor.lilly.com) India is part of that push. Moneycontrol reported on April 13 that Lilly wants to bring orforglipron to India, where company executive Winselow Tucker said Indian participation in the global Phase 3 ATTAIN-1 trial could help support a faster approval path. (moneycontrol.com) An oral pill could change who actually takes these medicines, because injectables require needles and cold-chain distribution while a small-molecule tablet does not. Lilly told investors that fewer than 1 in 10 eligible people are using a glucagon-like peptide-1 drug now, held back by access, stigma, and treatment complexity. (investor.lilly.com) The mental-health picture is also getting sharper. A Swedish national cohort study published online March 19 in *The Lancet Psychiatry* followed more than 95,000 people with depression or anxiety who were prescribed diabetes drugs between 2009 and 2022, including 22,480 who used glucagon-like peptide-1 drugs. (news.ki.se) Karolinska Institutet said semaglutide use was associated with a 42% lower risk of sickness absence or hospital care for psychiatric reasons, while liraglutide was linked to an 18% lower risk. The researchers also said the study was observational, so randomized clinical trials are still needed to show cause and effect. (news.ki.se) The result is a more complicated picture than the blockbuster sales pitch: the same drug class now comes with evidence of genetic non-response, broader global rollout through pills, and fresh signals that some patients may gain mental-health benefits alongside metabolic ones. (med.stanford.edu)